Evonik makes five generations healthier with EUDRAGIT® for drug delivery

In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, which was held at CPHI Frankfurt, across the categories from digital innovation to CEO of the year. 

Video introduction to Evonik Healthcare, a global development partner and enabling solutions provider.

Evonik launches RESOMER® Precise platform of custom functional excipients to precisely control the release profile of parenteral drug products

EUR 25 million first stage expected to be completed by mid-2021 as COVID-19 pandemic highlights need for more European capacity

Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of LNP formulations.

Evonik has officially opened a new facility for drying aqueous dispersions of EUDRAGIT® polymers at its site in Darmstadt.

EUDRACAP functional ready-to-fill capsules can optimize your release profile, protect your active ingredients, and help accelerate your speed to market.

Developing a delayed release formulation of acid-sensitive actives that can be used in solid dosage forms such as tablets, pellets and capsules can be costly. Usually several stages are involved starting from R&D development to scale up and validation steps, all of which require significant investment of time and money. Sourcing a ready-to-fill functional capsule is an effective way of saving costs, reducing time to market, and boosting the performance of oral drug delivery products. EUDRACAP is our recently launched non-animal-derived platform of functional, ready-to-fill capsules for fast-track development of sensitive drugs.